Decrease of Plasma Triglyceride-Rich Lipoprotein Remnants by Treatment with a Dipeptidyl Peptidase-4 Inhibitor in Diabetic Patients with Chronic Kidney Disease

2018 ◽  
Vol 32 ◽  
pp. 149-150
Author(s):  
Koichiro Homma ◽  
Joe Yoshizawa ◽  
Junichi Sasaki ◽  
Mamoru Yoshizawa ◽  
Yasuhiko Homma
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Dipeptidyl Peptidase ◽  
Plasma Triglyceride ◽  
Diabetic Patients ◽  
Dipeptidyl Peptidase 4 ◽  
Dipeptidyl Peptidase 4 Inhibitor ◽  
Triglyceride Rich Lipoprotein

scholarly journals The dipeptidyl peptidase-4 inhibitor teneligliptin reduces kidney damage from hypercholesterolemia in apolipoprotein E-deficient mice

RSC Advances ◽  
2017 ◽  
Vol 7 (14) ◽  
pp. 8702-8708 ◽  
Author(s):  
Hui Liu ◽  
Nan Li ◽  
Ying Liu ◽  
Jing Xing ◽  
Shuai Feng ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Risk Factor ◽  
Kidney Disease ◽  
Apolipoprotein E ◽  
Kidney Injury ◽  
Dipeptidyl Peptidase ◽  
Dipeptidyl Peptidase 4 ◽  
Established Risk Factor ◽  
Dipeptidyl Peptidase 4 Inhibitor ◽  
Deficient Mice

Hypercholesterolemia is a well-established risk factor for kidney injury that can lead to chronic kidney disease (CKD).

Sign in / Sign up

Export Citation Format

Share Document